恶性肿瘤高钙血症 - Suppr

Hypercalcemia of malignancy.

作者信息

Grill V, Martin T J

机构信息

St Vincent's Institute of Medical Research, Melbourne, Victoria 3065, Australia.

出版信息

Rev Endocr Metab Disord. 2000 Nov;1(4):253-63. doi: 10.1023/a:1026597816193.

DOI:10.1023/a:1026597816193

PMID:11706739

Abstract

摘要

相似文献

Hypercalcemia of malignancy.

Rev Endocr Metab Disord. 2000 Nov;1(4):253-63. doi: 10.1023/a:1026597816193.

[Pathophysiology and treatment of malignancy-associated hypercalcemia].

Nihon Rinsho. 2006 Jun 28;Suppl 2:161-4.

Parathyroid hormone measurements in hyperparathyroidism and hypercalcemia due to nonparathyroid cancers.

Wis Med J. 1971 Jun;70(6):159-61.

Cancer-associated hypercalcemia.

N Engl J Med. 1981 Apr 9;304(15):911-2. doi: 10.1056/nejm198104093041516.

Tumor hypercalcemia.

Calif Med. 1973 Jan;118(1):35-6.

[Hypercalcemia in patients with malignant tumor (author's transl)].

Rinsho Byori. 1975 May;23(5):371-4.

Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.

J Endocrinol Invest. 1997 Jul-Aug;20(7):404-9. doi: 10.1007/BF03347992.

Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: a case report.

Ann Oncol. 2000 Jan;11(1):97-100. doi: 10.1023/a:1008319323222.

Parathyroid hormone-related peptide and hypercalcemia of malignancy.

Cancer Treat Res. 1997;89:193-215. doi: 10.1007/978-1-4615-6355-6_10.

[Metabolic bone diseases: malignancy-associated hypercalcemia].

Nihon Rinsho. 1986 Nov;44(11):2467-72.

引用本文的文献

Small-Cell Lung Cancer Presenting as Hypercalcemia.

Cureus. 2025 Jul 20;17(7):e88367. doi: 10.7759/cureus.88367. eCollection 2025 Jul.

Review of Bone Metastasis in Gynecologic Malignancies: Evaluation and Treatment.

Curr Treat Options Oncol. 2025 May;26(5):331-340. doi: 10.1007/s11864-025-01312-w. Epub 2025 Apr 5.

Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy.

Endocrinol Metab (Seoul). 2025 Apr;40(2):289-298. doi: 10.3803/EnM.2024.2132. Epub 2025 Feb 4.

Clinical and Biochemical Profiles of Hospitalized Patients with Hypercalcaemia from a Tertiary Care Centre in North India.

touchREV Endocrinol. 2024 Oct;20(2):119-123. doi: 10.17925/EE.2024.20.2.15. Epub 2024 Oct 4.

Bone-homing metastatic breast cancer cells impair osteocytes' mechanoresponse in a 3D loading model.

Heliyon. 2023 Sep 21;9(10):e20248. doi: 10.1016/j.heliyon.2023.e20248. eCollection 2023 Oct.

Hypercalcemia-Leukocytosis syndrome and adenosquamous lung carcinoma: An overlooked conjugation.

Oncol Res. 2022 Jul 13;29(2):81-85. doi: 10.32604/or.2022.023450. eCollection 2021.

Granulocyte-colony stimulating factor producing cervical cancer with elevated levels of parathyroid hormone-related protein: a case report and literature review.

CEN Case Rep. 2024 Feb;13(1):45-52. doi: 10.1007/s13730-023-00788-5. Epub 2023 May 25.

Prevalence and Etiological Profile of Hypercalcemia in Hospitalized Adult Patients and Association with Mortality.

Indian J Endocrinol Metab. 2022 Sep-Oct;26(5):453-458. doi: 10.4103/ijem.ijem_223_21. Epub 2022 Nov 22.

Seizures Associated With Bone Density Conservation Agents.

J Pharm Technol. 2022 Apr;38(2):119-126. doi: 10.1177/87551225211070978. Epub 2022 Jan 26.

Hypercalcemia of Malignancy: Time to Pull the Brakes.

Indian J Surg Oncol. 2022 Mar;13(1):28-32. doi: 10.1007/s13193-020-01131-5. Epub 2020 Jun 11.

本文引用的文献

MITHRAMYCIN IN THE TREATMENT OF DISSEMINATED TESTICULAR NEOPLASMS.

N Engl J Med. 1965 Jan 21;272:111-8. doi: 10.1056/NEJM196501212720301.

Activated T lymphocytes support osteoclast formation in vitro.

Biochem Biophys Res Commun. 1999 Nov;265(1):144-50. doi: 10.1006/bbrc.1999.1623.

Breast cancer cells interact with osteoblasts to support osteoclast formation.

Endocrinology. 1999 Oct;140(10):4451-8. doi: 10.1210/endo.140.10.7037.

Parathyroid hormone-related protein mRNA and protein expression in multiple myeloma: a case report.

J Bone Miner Res. 1998 Oct;13(10):1640-3. doi: 10.1359/jbmr.1998.13.10.1640.

A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.

Endocrinology. 1998 Oct;139(10):4424-7. doi: 10.1210/endo.139.10.6331.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Cell. 1998 Apr 17;93(2):165-76. doi: 10.1016/s0092-8674(00)81569-x.

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602. doi: 10.1073/pnas.95.7.3597.

The noncalcemic vitamin D analogs EB1089 and 22-oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene expression in a lung cancer cell line.

Endocrinology. 1998 Mar;139(3):1046-53. doi: 10.1210/endo.139.3.5774.

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.

J Biol Chem. 1997 Oct 3;272(40):25190-4. doi: 10.1074/jbc.272.40.25190.

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Biochem Biophys Res Commun. 1997 May 8;234(1):137-42. doi: 10.1006/bbrc.1997.6603.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Hypercalcemia of malignancy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献